mechanism	In the presence of <e10> ketoconazole </e10> , there was #- and #-fold increase in C (max) and AUC of <e20> panobinostat </e20> , respectively.
mechanism	<e10> Moxifloxacin </e10> and Lomefloxacin reacts faster with <e20> sucralfate </e20> and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
mechanism	<e10> Moxifloxacin </e10> and Lomefloxacin reacts faster with sucralfate and <e21> gelusil </e21> in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
mechanism	<e10> Moxifloxacin </e10> and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with <e20> erythromycin </e20> in basic media and multi-minerals in neutral media.
mechanism	<e10> Moxifloxacin </e10> and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and <e22> multi-minerals </e22> in neutral media.
mechanism	Moxifloxacin and <e10> Lomefloxacin </e10> reacts faster with <e20> sucralfate </e20> and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
mechanism	Moxifloxacin and <e10> Lomefloxacin </e10> reacts faster with sucralfate and <e21> gelusil </e21> in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
mechanism	Moxifloxacin and <e10> Lomefloxacin </e10> reacts faster with sucralfate and gelusil in acidic media whereas with <e20> erythromycin </e20> in basic media and multi-minerals in neutral media.
mechanism	Moxifloxacin and <e10> Lomefloxacin </e10> reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and <e22> multi-minerals </e22> in neutral media.
mechanism	<e10> Ticlopidine </e10> treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0- )) of oral <e20> ketamine </e20> by #-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine .
mechanism	<e10> Paroxetine </e10> and fluoxetine reduce the plasma concentration of <e23> endoxifen </e23> by about 50%.
mechanism	Paroxetine and <e10> fluoxetine </e10> reduce the plasma concentration of <e23> endoxifen </e23> by about 50%.
mechanism	Systemic and apparent oral <e10> midazolam </e10> clearance were 24% (269 # vs, # # ml/min, P = #) and 31% (479 # vs, # # ml/min, P = #), respectively, lower in <e20> cyclosporine </e20> -treated patients (n = 20) than in matched tacrolimus -treated patients (n = 20).
mechanism	Concomitant use of <e10> omeprazole </e10> and <e20> clopidogrel </e20> was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme.
mechanism	<e10> Pantoprazole </e10> has a much weaker effect on <e20> clopidogrel </e20> 's pharmacokinetics and on platelet reactivity during concomitant use.
mechanism	<e10> Calcium </e10> is the only known component in the diet that may affect absorption of both <e20> nonheme_iron </e20> and heme_iron .
mechanism	<e10> Calcium </e10> is the only known component in the diet that may affect absorption of both nonheme_iron and <e20> heme_iron </e20> .
mechanism	However, the evidence for a <e10> calcium </e10> effect on <e20> iron </e20> absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies.
mechanism	<e10> Calcium </e10> doses # mg diminished <e20> nonheme_iron </e20> absorption by an average of #%.
mechanism	A <e10> calcium </e10> dose of # mg diminished absorption of # mg <e20> heme_iron </e20> by #%.
mechanism	In conclusion, we demonstrated an isolated effect of <e10> calcium </e10> (as chloride) on absorption of # mg of iron provided as <e20> nonheme_iron </e20> (as sulfate) and heme_iron (as CRBC).
mechanism	In conclusion, we demonstrated an isolated effect of <e10> calcium </e10> (as chloride) on absorption of # mg of iron provided as nonheme_iron (as sulfate) and <e20> heme_iron </e20> (as CRBC).
mechanism	<e10> Ibuprofen </e10> plasma concentration was also increased when it was administered with <e23> piperine </e23> .
mechanism	The synergistic antinociception activity of <e10> ibuprofen </e10> when administered with <e23> piperine </e23> can be attributed to increased plasma concentration of ibuprofen .
mechanism	<e10> Ethanol </e10> decreases the elimination of <e20> abacavir </e20> causing an increase in overall exposure , The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir .
mechanism	In a study of # HIV-infected patients receiving <e10> methadone </e10> -maintenance therapy (40 mg and # mg daily) with # mg of <e21> ZIAGEN </e21> twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%).
mechanism	Cholestyramine : Concomitant <e10> cholestyramine </e10> administration decreased the mean AUC of total <e20> ezetimibe </e20> approximately 55%.
mechanism	Fenofibrate : In a pharmacokinetic study, concomitant <e10> fenofibrate </e10> administration increased total <e20> ezetimibe </e20> concentrations approximately #-fold.
mechanism	Cyclosporine : The total <e10> ezetimibe </e10> level increased 12-fold in one renal transplant patient receiving multiple medications, including <e20> cyclosporine </e20> .
mechanism	<e11> DIFLUCAN </e11> reduces the metabolism of <e20> tolbutamide </e20> , glyburide , and glipizide and increases the plasma concentration of these agents.
mechanism	<e11> DIFLUCAN </e11> reduces the metabolism of tolbutamide , <e20> glyburide </e20> , and glipizide and increases the plasma concentration of these agents.
mechanism	<e11> DIFLUCAN </e11> reduces the metabolism of tolbutamide , glyburide , and <e20> glipizide </e20> and increases the plasma concentration of these agents.
mechanism	Phenytoin : <e11> DIFLUCAN </e11> increases the plasma concentrations of <e20> phenytoin </e20> .
mechanism	Cyclosporine : <e11> DIFLUCAN </e11> may significantly increase <e20> cyclosporine </e20> levels in renal transplant patients with or without renal impairment.
mechanism	Rifampin : <e10> Rifampin </e10> enhances the metabolism of concurrently administered <e21> DIFLUCAN </e21> .
mechanism	Theophylline : <e11> DIFLUCAN </e11> increases the serum concentrations of <e20> theophylline </e20> .
mechanism	Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that <e11> DIFLUCAN </e11> taken in doses of # mg per day or greater significantly increases plasma levels of <e20> terfenadine </e20> when taken concomitantly.
mechanism	A controlled study found that concomitant <e10> fluconazole </e10> # mg once daily and <e20> cisapride </e20> # mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.
mechanism	Astemizole : The use of <e10> fluconazole </e10> in patients concurrently taking <e20> astemizole </e20> or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.
mechanism	Short-acting_Benzodiazepines : Following oral administration of <e10> midazolam </e10> , <e20> fluconazole </e20> resulted in substantial increases in midazolam concentrations and psychomotor effects.
mechanism	<e10> Fluconazole </e10> tablets coadministered with <e20> ethinyl_estradiol </e20> - and levonorgestrel -containing oral contraceptives produced an overall mean increase in ethinyl_estradiol and levonorgestrel levels;
mechanism	<e10> Fluconazole </e10> tablets coadministered with ethinyl_estradiol - and <e20> levonorgestrel </e20> -containing oral contraceptives produced an overall mean increase in ethinyl_estradiol and levonorgestrel levels;
mechanism	While there is evidence that <e10> fluconazole </e10> can inhibit the metabolism of <e20> ethinyl_estradiol </e20> and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl_estradiol or levonorgestrel metabolism.
mechanism	While there is evidence that <e10> fluconazole </e10> can inhibit the metabolism of ethinyl_estradiol and <e20> levonorgestrel </e20> , there is no evidence that fluconazole is a net inducer of ethinyl_estradiol or levonorgestrel metabolism.
mechanism	Preliminary evidence suggests that <e10> cimetidine </e10> inhibits <e20> mebendazole </e20> metabolism and may result in an increase in plasma concentrations of mebendazole .
mechanism	<e10> Aminoglutethimide </e10> administered concomitantly with <e21> depo-subQ_provera_104 </e21> may significantly decrease the serum concentrations of MPA .
mechanism	A pharmacokinetic study demonstrated that coadministration of <e10> megestrol_acetate </e10> and <e20> indinavir </e20> results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir .
mechanism	Aspirin : Concomitant administration of <e11> aspirin </e11> (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of <e20> meloxicam </e20> .
mechanism	Cholestyramine : Pretreatment for four days with <e10> cholestyramine </e10> significantly increased the clearance of <e20> meloxicam </e20> by 50%.
mechanism	Lithium : In clinical trials, <e12> NSAIDs </e12> have produced an elevation of plasma <e20> lithium </e20> levels and a reduction in renal lithium clearance.
mechanism	In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving <e10> lithium </e10> doses ranging from # to # mg BID with <e20> meloxicam </e20> # mg QD as compared to subjects receiving lithium alone.
mechanism	<e12> Anticholinergic_agents </e12> may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of <e20> digoxin </e20> ;
mechanism	Because <e10> antacids </e10> may interfere with the absorption of <e22> anticholinergic_agents </e22> , simultaneous use of these drugs should be avoided.
mechanism	<e10> Probenecid </e10> competes with <e20> meropenem </e20> for active tubular secretion and thus inhibits the renal excretion of meropenem .
mechanism	There is evidence that <e10> meropenem </e10> may reduce serum levels of <e20> valproic_acid </e20> to subtherapeutic levels (therapeutic range considered to be # to # g/mL total valproate ).
mechanism	Since Celontin ( methsuximide ) may interact with concurrently administered antiepileptic_drugs , periodic serum level determinations of these drugs may be necessary (eg <e10> methsuximide </e10> may increase the plasma concentrations of <e20> phenytoin </e20> and phenobarbital ).
mechanism	Since Celontin ( methsuximide ) may interact with concurrently administered antiepileptic_drugs , periodic serum level determinations of these drugs may be necessary (eg <e10> methsuximide </e10> may increase the plasma concentrations of phenytoin and <e20> phenobarbital </e20> ).
mechanism	<e10> Lithium </e10> renal clearance is reduced by <e22> thiazides </e22> , increasing the risk of lithium toxicity.
mechanism	Several studies demonstrate a decrease in the bioavailability of <e10> methyldopa </e10> when it is ingested with <e20> ferrous_sulfate </e20> or ferrous_gluconate .
mechanism	Several studies demonstrate a decrease in the bioavailability of <e10> methyldopa </e10> when it is ingested with ferrous_sulfate or <e20> ferrous_gluconate </e20> .
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of <e22> coumarin_anticoagulants </e22> , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ), phenylbutazone , and tricyclic_drugs ( imipramine , clomipramine , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , <e22> anticonvulsants </e22> ( phenobarbital , diphenylhydantoin , primidone ), phenylbutazone , and tricyclic_drugs ( imipramine , clomipramine , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , anticonvulsants ( <e20> phenobarbital </e20> , diphenylhydantoin , primidone ), phenylbutazone , and tricyclic_drugs ( imipramine , clomipramine , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , anticonvulsants ( phenobarbital , <e20> diphenylhydantoin </e20> , primidone ), phenylbutazone , and tricyclic_drugs ( imipramine , clomipramine , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , <e20> primidone </e20> ), phenylbutazone , and tricyclic_drugs ( imipramine , clomipramine , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ), <e20> phenylbutazone </e20> , and tricyclic_drugs ( imipramine , clomipramine , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ), phenylbutazone , and <e22> tricyclic_drugs </e22> ( imipramine , clomipramine , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ), phenylbutazone , and tricyclic_drugs ( <e20> imipramine </e20> , clomipramine , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ), phenylbutazone , and tricyclic_drugs ( imipramine , <e20> clomipramine </e20> , desipramine ).
mechanism	Human pharmacologic studies have shown that <e11> Ritalin </e11> may inhibit the metabolism of coumarin_anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ), phenylbutazone , and tricyclic_drugs ( imipramine , clomipramine , <e20> desipramine </e20> ).
mechanism	Mutual inhibition of metabolism occurs with concurrent use of <e10> cyclosporin </e10> and <e20> methylprednisolone </e20> ;
mechanism	Drugs that induce hepatic enzymes such as <e10> phenobarbital </e10> , phenytoin , and rifampin may increase the clearance of <e20> methylprednisolone </e20> and may require increased in methylprednisolone dose to achieve the desired response.
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , <e10> phenytoin </e10> , and rifampin may increase the clearance of <e20> methylprednisolone </e20> and may require increased in methylprednisolone dose to achieve the desired response.
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and <e10> rifampin </e10> may increase the clearance of <e20> methylprednisolone </e20> and may require increased in methylprednisolone dose to achieve the desired response.
mechanism	Drugs such as <e10> troleandomycin </e10> and ketoconazole may inhibit the metabolism of <e20> methylprednisolone </e20> and thus decrease its clearance.
mechanism	Drugs such as troleandomycin and <e10> ketoconazole </e10> may inhibit the metabolism of <e20> methylprednisolone </e20> and thus decrease its clearance.
mechanism	<e10> Methylprednisolone </e10> may increase the clearance of chronic high dose <e21> aspirin </e21> .
mechanism	Absorption of drugs from the stomach may be diminished (e,g,, <e10> digoxin </e10> ) by <e22> metoclopramide </e22> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e,g,, acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ).
mechanism	Absorption of drugs from the stomach may be diminished (e,g,, digoxin ) by <e12> metoclopramide </e12> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e,g,, <e20> acetaminophen </e20> , tetracycline , levodopa , ethanol , cyclosporine ).
mechanism	The metabolism of <e11> Metopirone </e11> is accelerated by <e20> phenytoin </e20> ;
mechanism	<e11> Metopirone </e11> inhibits the glucuronidation of <e20> acetaminophen </e20> and could possibly potentiate acetaminophen toxicity.
mechanism	In a formal, single-dose interaction study (n = # males) the clearance of <e10> mexiletine </e10> was decreased by 38% following the coadministration of <e20> fluvoxamine </e20> , an inhibitor of CYP1A2.
mechanism	When <e10> phenytoin </e10> or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with <e21> Mexitil </e21> , lowered Mexitil plasma levels have been reported.
mechanism	When phenytoin or other hepatic enzyme inducers such as <e10> rifampin </e10> and phenobarbital have been taken concurrently with <e21> Mexitil </e21> , lowered Mexitil plasma levels have been reported.
mechanism	When phenytoin or other hepatic enzyme inducers such as rifampin and <e10> phenobarbital </e10> have been taken concurrently with <e21> Mexitil </e21> , lowered Mexitil plasma levels have been reported.
mechanism	Concurrent administration of <e10> cimetidine </e10> and <e21> Mexitil </e21> has been reported to increase, decrease, or leave unchanged Mexitil plasma levels;
mechanism	Mexitil does not alter serum digoxin levels but <e10> magnesium-aluminum_hydroxide </e10> , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum <e20> digoxin </e20> levels.
mechanism	Concurrent use of <e11> Mexitil </e11> and <e20> theophylline </e20> may lead to increased plasma theophylline levels.
mechanism	This increase was observed at the first test point which was the second day after starting Mexitil , <e10> Theophylline </e10> plasma levels returned to pre- Mexitil values within # hours after discontinuing <e21> Mexitil </e21> , If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil dose is changed.
mechanism	Additionally, in one controlled study in five normal subjects and seven patients, the clearance of <e10> caffeine </e10> was decreased 50% following the administration of <e21> Mexitil </e21> .
mechanism	<e11> Posicor </e11> inhibits some of the liver's ability to metabolize some other drugs - <e20> terfenadine </e20> , astemizole , cisapride , cyclosporine , and tricyclic_antidepressants .
mechanism	<e11> Posicor </e11> inhibits some of the liver's ability to metabolize some other drugs - terfenadine , <e20> astemizole </e20> , cisapride , cyclosporine , and tricyclic_antidepressants .
mechanism	<e11> Posicor </e11> inhibits some of the liver's ability to metabolize some other drugs - terfenadine , astemizole , <e20> cisapride </e20> , cyclosporine , and tricyclic_antidepressants .
mechanism	<e11> Posicor </e11> inhibits some of the liver's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , <e20> cyclosporine </e20> , and tricyclic_antidepressants .
mechanism	<e11> Posicor </e11> inhibits some of the liver's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and <e22> tricyclic_antidepressants </e22> .
mechanism	<e10> Sirolimus </e10> AUC was increased by 21% with no effect on Cmax in the presence of steady-state <e21> MYCAMINE </e21> compared with sirolimus alone.
mechanism	<e10> Nifedipine </e10> AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state <e21> MYCAMINE </e21> compared with nifedipine alone.
mechanism	Drugs such as <e10> erythromycin </e10> , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e20> midazolam </e20> .
mechanism	Drugs such as erythromycin , <e10> diltiazem </e10> , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e20> midazolam </e20> .
mechanism	Drugs such as erythromycin , diltiazem , <e10> verapamil </e10> , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e20> midazolam </e20> .
mechanism	Drugs such as erythromycin , diltiazem , verapamil , <e10> ketoconazole </e10> , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e20> midazolam </e20> .
mechanism	Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , <e10> fluconazole </e10> and itraconazole were shown to significantly increase the C max and AUC of orally administered <e20> midazolam </e20> .
mechanism	Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and <e10> itraconazole </e10> were shown to significantly increase the C max and AUC of orally administered <e20> midazolam </e20> .
mechanism	Although not studied, the potent cytochrome P450 3A4 inhibitors <e10> ritonavir </e10> and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of <e20> midazolam </e20> .
mechanism	Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and <e10> nelfinavir </e10> may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of <e20> midazolam </e20> .
mechanism	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as <e10> rifampin </e10> , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral <e20> midazolam </e20> in adult studies.
mechanism	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin , <e10> carbamazepine </e10> , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral <e20> midazolam </e20> in adult studies.
mechanism	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin , carbamazepine , and <e10> phenytoin </e10> , induce metabolism and caused a markedly decreased C max and AUC of oral <e20> midazolam </e20> in adult studies.
mechanism	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e13> desglymidodrine </e13> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e20> metformin </e20> , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine .
mechanism	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e13> desglymidodrine </e13> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , <e20> cimetidine </e20> , ranitidine , procainamide , triamterene , flecainide , and quinidine .
mechanism	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e13> desglymidodrine </e13> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , <e20> ranitidine </e20> , procainamide , triamterene , flecainide , and quinidine .
mechanism	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e13> desglymidodrine </e13> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , <e20> procainamide </e20> , triamterene , flecainide , and quinidine .
mechanism	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e13> desglymidodrine </e13> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , <e20> triamterene </e20> , flecainide , and quinidine .
mechanism	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e13> desglymidodrine </e13> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , <e20> flecainide </e20> , and quinidine .
mechanism	ProAmatine , Alpha-adrenergic_blocking_agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine , Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e13> desglymidodrine </e13> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and <e20> quinidine </e20> .
mechanism	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that <e10> ketoconazole </e10> , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism (increasing serum levels of <e20> mifepristone </e20> ).
mechanism	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole , <e10> itraconazole </e10> , erythromycin , and grapefruit juice may inhibit its metabolism (increasing serum levels of <e20> mifepristone </e20> ).
mechanism	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole , itraconazole , <e10> erythromycin </e10> , and grapefruit juice may inhibit its metabolism (increasing serum levels of <e20> mifepristone </e20> ).
mechanism	John s Wort, and certain <e12> anticonvulsants </e12> ( phenytoin , phenobarbital , carbamazepine ) may induce <e20> mifepristone </e20> metabolism (lowering serum levels of mifepristone ).
mechanism	John s Wort, and certain anticonvulsants ( <e10> phenytoin </e10> , phenobarbital , carbamazepine ) may induce <e20> mifepristone </e20> metabolism (lowering serum levels of mifepristone ).
mechanism	John s Wort, and certain anticonvulsants ( phenytoin , <e10> phenobarbital </e10> , carbamazepine ) may induce <e20> mifepristone </e20> metabolism (lowering serum levels of mifepristone ).
mechanism	John s Wort, and certain anticonvulsants ( phenytoin , phenobarbital , <e10> carbamazepine </e10> ) may induce <e20> mifepristone </e20> metabolism (lowering serum levels of mifepristone ).
mechanism	While co-administration of <e11> ZAVESCA </e11> appeared to increase the clearance of <e21> Cerezyme </e21> by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme .
mechanism	Absorption of <e12> tetracyclines </e12> is impaired by antacids containing <e20> aluminum </e20> , calcium or magnesium , and iron -containing preparations.
mechanism	Absorption of <e12> tetracyclines </e12> is impaired by antacids containing aluminum , <e20> calcium </e20> or magnesium , and iron -containing preparations.
mechanism	Absorption of <e12> tetracyclines </e12> is impaired by antacids containing aluminum , calcium or <e20> magnesium </e20> , and iron -containing preparations.
mechanism	Absorption of <e12> tetracyclines </e12> is impaired by antacids containing aluminum , calcium or magnesium , and <e20> iron </e20> -containing preparations.
mechanism	Alcohol : Concomitant administration of <e10> alcohol </e10> (equivalent to # g) had a minimal effect on plasma levels of <e20> mirtazapine </e20> (15 mg) in # healthy male subjects.
mechanism	Accordingly, patients should be advised to avoid alcohol while taking REMERON_SolTab , Diazepam : Concomitant administration of <e10> diazepam </e10> (15 mg) had a minimal effect on plasma levels of <e20> mirtazapine </e20> (15 mg) in # healthy subjects.
mechanism	<e10> Mitotane </e10> has been reported to accelerate the metabolism of <e20> warfarin </e20> by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin .
mechanism	However, <e10> ketoconazole </e10> , a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of <e20> mometasone_furoate </e20> during concomitant dosing.
mechanism	Antacids : Absorption of a single dose of <e11> Myfortic </e11> was decreased when administered to # stable renal transplant patients also taking <e20> magnesium </e20> - aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
mechanism	Antacids : Absorption of a single dose of <e11> Myfortic </e11> was decreased when administered to # stable renal transplant patients also taking magnesium - <e20> aluminum </e20> containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
mechanism	However, in a drug-drug interaction study, mean <e10> levonorgesterol </e10> AUC was decreased by 15% when coadministered with <e20> mycophenolate_mofetil </e20> .
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i,e,, <e10> phenytoin </e10> , carbamazepine , and rifampicin ), the clearance of <e20> ondansetron </e20> was significantly increased and ondansetron blood concentrations were decreased.
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i,e,, <e10> phenytoin </e10> , carbamazepine , and rifampicin ), the clearance of ondansetron was significantly increased and <e20> ondansetron </e20> blood concentrations were decreased.
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i,e,, phenytoin , <e10> carbamazepine </e10> , and rifampicin ), the clearance of <e20> ondansetron </e20> was significantly increased and ondansetron blood concentrations were decreased.
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i,e,, phenytoin , <e10> carbamazepine </e10> , and rifampicin ), the clearance of ondansetron was significantly increased and <e20> ondansetron </e20> blood concentrations were decreased.
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i,e,, phenytoin , carbamazepine , and <e10> rifampicin </e10> ), the clearance of <e20> ondansetron </e20> was significantly increased and ondansetron blood concentrations were decreased.
mechanism	Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 (i,e,, phenytoin , carbamazepine , and <e10> rifampicin </e10> ), the clearance of ondansetron was significantly increased and <e20> ondansetron </e20> blood concentrations were decreased.
mechanism	Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when <e11> XENICAL </e11> was coadministered with <e20> cyclosporine </e20> .
mechanism	Fat-soluble_Vitamin_Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in <e10> beta-carotene </e10> supplement absorption when concomitantly administered with <e21> XENICAL </e21> .
mechanism	<e11> XENICAL </e11> inhibited absorption of a <e20> vitamin_E_acetate </e20> supplement by approximately 60%.
mechanism	Therefore, as <e12> vitamin_K </e12> absorption may be decreased with <e21> XENICAL </e21> , patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.
mechanism	Increases of <e10> 5-FU </e10> plasma concentrations by approximately 20% have been observed with doses of # mg/m2 <e21> ELOXATIN </e21> dosed every # weeks.
mechanism	Warfarin : A multidose study of <e10> oxandrolone </e10> , given as # or # mg BID in # healthy subjects concurrently treated with <e20> warfarin </e20> , resulted in a mean increase in S-warfarin half-life from # to # hours and AUC from # to # ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.
mechanism	Oral hypoglycemic_agents <e10> Oxandrolone </e10> may inhibit the metabolism of oral <e22> hypoglycemic_agents </e22> .
mechanism	Mean oxybutynin_chloride plasma concentrations were approximately # fold higher when <e11> DITROPAN_XL </e11> was administered with <e20> ketoconazole </e20> , a potent CYP3A4 inhibitor.
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as <e12> antimycotic_agents </e12> (e,g,, itraconazole and miconazole ) or macrolide_antibiotics (e,g,, erythromycin and clarithromycin ), may alter <e20> oxybutynin </e20> mean pharmacokinetic parameters (i,e,, Cmax and AUC).
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic_agents (e,g,, <e10> itraconazole </e10> and miconazole ) or macrolide_antibiotics (e,g,, erythromycin and clarithromycin ), may alter <e20> oxybutynin </e20> mean pharmacokinetic parameters (i,e,, Cmax and AUC).
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic_agents (e,g,, itraconazole and <e10> miconazole </e10> ) or macrolide_antibiotics (e,g,, erythromycin and clarithromycin ), may alter <e20> oxybutynin </e20> mean pharmacokinetic parameters (i,e,, Cmax and AUC).
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic_agents (e,g,, itraconazole and miconazole ) or <e12> macrolide_antibiotics </e12> (e,g,, erythromycin and clarithromycin ), may alter <e20> oxybutynin </e20> mean pharmacokinetic parameters (i,e,, Cmax and AUC).
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic_agents (e,g,, itraconazole and miconazole ) or macrolide_antibiotics (e,g,, <e10> erythromycin </e10> and clarithromycin ), may alter <e20> oxybutynin </e20> mean pharmacokinetic parameters (i,e,, Cmax and AUC).
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic_agents (e,g,, itraconazole and miconazole ) or macrolide_antibiotics (e,g,, erythromycin and <e10> clarithromycin </e10> ), may alter <e20> oxybutynin </e20> mean pharmacokinetic parameters (i,e,, Cmax and AUC).
mechanism	Because of profound and long lasting inhibition of gastric acid secretion, <e10> pantoprazole </e10> may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, <e20> ketoconazole </e20> , ampicillin esters, and iron salts).
mechanism	Because of profound and long lasting inhibition of gastric acid secretion, <e10> pantoprazole </e10> may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole , <e20> ampicillin </e20> esters, and iron salts).
mechanism	Because of profound and long lasting inhibition of gastric acid secretion, <e10> pantoprazole </e10> may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole , ampicillin esters, and <e20> iron </e20> salts).
mechanism	A multiple dose drug-drug interaction study demonstrated that <e10> ketoconazole </e10> approximately doubled <e20> paricalcitol </e20> AUC0- , Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
mechanism	Drugs that impair intestinal absorption of <e12> fat-soluble_vitamins </e12> , such as <e20> cholestyramine </e20> , may interfere with the absorption of Zemplar Capsules.
mechanism	Drugs that impair intestinal absorption of fat-soluble_vitamins , such as <e10> cholestyramine </e10> , may interfere with the absorption of <e21> Zemplar </e21> Capsules.
mechanism	In a pharmacokinetic study of # chronic hepatitis C patients concomitantly receiving <e10> methadone </e10> , treatment with <e21> PEG-Intron </e21> once weekly for # weeks was associated with a mean increase of 16% in methadone AUC;
mechanism	In clinical studies, patients on <e12> opioids </e12> often needed higher serum <e20> pegvisomant </e20> concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids .
mechanism	Concomitant administration of substances that are also tubularly secreted (e,g,, <e10> probenecid </e10> ) could potentially result in delayed clearance of <e21> ALIMTA </e21> .
mechanism	<e12> Penicillin </e12> blood levels may be prolonged by concurrent administration of <e20> probenecid </e20> which blocks the renal tubular secretion of penicillins .
mechanism	Concomitant administration of <e11> TRENTAL </e11> and <e20> theophylline </e20> -containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.
mechanism	Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets, but an effect of <e10> digoxin </e10> on the plasma concentration of <e20> perindopril </e20> / perindoprilat has not been excluded.
mechanism	Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets, but an effect of <e10> digoxin </e10> on the plasma concentration of perindopril / <e23> perindoprilat </e23> has not been excluded.
mechanism	<e10> Pindolol </e10> has been shown to increase serum <e20> thioridazine </e20> levels when both drugs are co-administered.
mechanism	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e11> FELDENE </e11> is administered in conjunction with <e21> aspirin </e21> (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels , Nonsteroidal_anti-inflammatory_agents , including FELDENE , have been reported to increase steady state plasma lithium levels.
mechanism	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels , <e12> Nonsteroidal_anti-inflammatory_agents </e12> , including FELDENE , have been reported to increase steady state plasma <e20> lithium </e20> levels.
mechanism	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels , Nonsteroidal_anti-inflammatory_agents , including <e11> FELDENE </e11> , have been reported to increase steady state plasma <e20> lithium </e20> levels.
mechanism	Cimetidine : <e10> Cimetidine </e10> , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in <e20> pramipexole </e20> AUC and a 40% increase in half-life (N= 12).
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, <e10> cimetidine </e10> , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e20> pramipexole </e20> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , <e10> ranitidine </e10> , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e20> pramipexole </e20> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , <e10> diltiazem </e10> , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of <e20> pramipexole </e20> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , <e10> triamterene </e10> , verapamil , quinidine , and quinine ) decreases the oral clearance of <e20> pramipexole </e20> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , <e10> verapamil </e10> , quinidine , and quinine ) decreases the oral clearance of <e20> pramipexole </e20> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , <e10> quinidine </e10> , and quinine ) decreases the oral clearance of <e20> pramipexole </e20> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and <e10> quinine </e10> ) decreases the oral clearance of <e20> pramipexole </e20> by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, <e12> cephalosporins </e12> , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e20> pramipexole </e20> .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , <e12> penicillins </e12> , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e20> pramipexole </e20> .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , <e10> indomethacin </e10> , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of <e20> pramipexole </e20> .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , <e10> hydrochlorothiazide </e10> , and chlorpropamide ) are likely to have little effect on the oral clearance of <e20> pramipexole </e20> .
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e,g,, cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e,g,, cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and <e10> chlorpropamide </e10> ) are likely to have little effect on the oral clearance of <e20> pramipexole </e20> .
mechanism	Mixing SYMLIN and Insulin The pharmacokinetic parameters of <e11> SYMLIN </e11> were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant <e20> human_insulin </e20> immediately prior to injection.
mechanism	Drugs that induce hepatic enzymes such as <e10> phenobarbital </e10> , phenytoin and rifampin may increase the clearance of <e22> corticosteroids </e22> and may require increases in corticosteroid dose to achieve the desired response.
mechanism	Drugs that induce hepatic enzymes such as <e10> phenobarbital </e10> , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in <e22> corticosteroid </e22> dose to achieve the desired response.
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , <e10> phenytoin </e10> and rifampin may increase the clearance of <e22> corticosteroids </e22> and may require increases in corticosteroid dose to achieve the desired response.
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , <e10> phenytoin </e10> and rifampin may increase the clearance of corticosteroids and may require increases in <e22> corticosteroid </e22> dose to achieve the desired response.
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and <e10> rifampin </e10> may increase the clearance of <e22> corticosteroids </e22> and may require increases in corticosteroid dose to achieve the desired response.
mechanism	Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and <e10> rifampin </e10> may increase the clearance of corticosteroids and may require increases in <e22> corticosteroid </e22> dose to achieve the desired response.
mechanism	Drugs such as <e10> troleandomycin </e10> and ketoconazole may inhibit the metabolism of <e22> corticosteroids </e22> and thus decrease their clearance.
mechanism	Drugs such as troleandomycin and <e10> ketoconazole </e10> may inhibit the metabolism of <e22> corticosteroids </e22> and thus decrease their clearance.
mechanism	<e12> Corticosteroids </e12> may increase the clearance of chronic high dose <e21> aspirin </e21> .
mechanism	Anticholinesterases : Concurrent use of procaine_hydrochloride and anticholinesterase_agents may result in increased systemic toxicity since <e12> anticholinesterases </e12> inhibit the breakdown of <e20> procaine_hydrochloride </e20> .
mechanism	Hyaluronidase : <e10> Hyaluronidase </e10> may increase the diffusion rate of <e20> procaine_hydrochloride </e20> , resulting in a decreased time of onset, but an increase in systemic toxicity.
mechanism	Acetazolamide : Concurrent use of <e10> acetazolamide </e10> and <e20> procaine_hydrochloride </e20> may extend the plasma half-life of procaine .
mechanism	Concomitant administration of <e10> propranolol </e10> with <e22> phenothiazines </e22> results in increased plasma levels of both drugs.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> causes a 60% reduction in the absorption and enterohepatic cycling of <e20> raloxifene </e20> and should not be coadministered with EVISTA .
mechanism	Coadministration of <e11> TRITEC </e11> with <e20> clarithromycin </e20> resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14-_hydroxy-_clarithromycin plasma concentrations (31%).
mechanism	Coadministration with a high dose of <e12> antacid </e12> (170 mEq) results in a 28% decrease in plasma concentrations of <e20> ranitidine </e20> and may decrease plasma concentrations of bismuth from TRITEC .
mechanism	Coadministration with a high dose of <e12> antacid </e12> (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from <e21> TRITEC </e21> .
mechanism	Co-administration of oral <e10> ketoconazole </e10> # mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of <e20> retapamulin </e20> ointment, 1% on the abraded skin of healthy adult males.
mechanism	Interactions for Vitamin_B2 ( Riboflavin ): <e10> Alcohol </e10> - impairs the intestinal absorption of <e20> riboflavin </e20>
mechanism	<e10> Probenecid </e10> - concurrent use decreases gastrointestinal absorption of <e20> riboflavin </e20> ;
mechanism	When a single # mg dose of <e10> rimantadine_HCl </e10> was administered one hour after the initiation of <e20> Cimetidine </e20> (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ).
mechanism	Coadministration with <e10> acetaminophen </e10> reduced the peak concentration and AUC values for <e20> rimantadine </e20> by approximately 11%.
mechanism	Peak plasma concentrations and AUC of <e10> rimantadine </e10> were reduced approximately 10% in the presence of <e21> aspirin </e21> .
mechanism	In vivo, the plasma clearance of <e10> ropivacaine </e10> was reduced by 70% during coadministration of <e20> fluvoxamine </e20> (25 mg bid for # days), a selective and potent CYP1A2 inhibitor.
mechanism	Coadministration of a selective and potent inhibitor of CYP3A4, <e10> ketoconazole </e10> (100 mg bid for # days with ropivacaine infusion administered # hour after ketoconazole ) caused a 15% reduction in in-vivo plasma clearance of <e20> ropivacaine </e20> .
mechanism	An inhibitor of CYP2C8 (such as <e10> gemfibrozil </e10> ) may increase the AUC of <e20> rosiglitazone </e20> and an inducer of CYP2C8 (such as rifampin ) may decrease the AUC of rosiglitazone .
mechanism	An inhibitor of CYP2C8 (such as gemfibrozil ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as <e10> rifampin </e10> ) may decrease the AUC of <e20> rosiglitazone </e20> .
mechanism	- Cisapride , pimozide : Other drugs such as <e10> cisapride </e10> or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some <e22> macrolide_antibacterials </e22> .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably <e20> penicillin </e20> , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , <e20> thiopental </e20> , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , thiopental , <e20> thyroxine </e20> , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , <e20> triiodothyronine </e20> , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , triiodothyronine , <e20> phenytoin </e20> , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , <e20> sulfinpyrazone </e20> , naproxen , warfarin , methotrexate , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , <e20> naproxen </e20> , warfarin , methotrexate , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , <e20> warfarin </e20> , methotrexate , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , <e20> methotrexate </e20> , and possibly corticosteroids .
mechanism	<e12> Salicylate </e12> competes with a number of drugs for protein binding sites, notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly <e22> corticosteroids </e22> .
mechanism	Digoxin : There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of <e10> digoxin </e10> with the co-administration of # mg <e20> sitagliptin </e20> for # days.
mechanism	Limited published data indicate that <e10> GH </e10> treatment increases cytochrome P450 (CP450) mediated <e20> antipyrine </e20> clearance in man.
mechanism	These data suggest that <e10> GH </e10> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e,g,, <e22> corticosteroids </e22> , sex_steroids , anticonvulsants , cyclosporin ).
mechanism	These data suggest that <e10> GH </e10> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e,g,, corticosteroids , <e22> sex_steroids </e22> , anticonvulsants , cyclosporin ).
mechanism	These data suggest that <e10> GH </e10> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e,g,, corticosteroids , sex_steroids , <e22> anticonvulsants </e22> , cyclosporin ).
mechanism	These data suggest that <e10> GH </e10> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e,g,, corticosteroids , sex_steroids , anticonvulsants , <e20> cyclosporin </e20> ).
mechanism	Concomitant treatment with <e11> NEXAVAR </e11> resulted in a 21% increase in the AUC of <e20> doxorubicin </e20> .
mechanism	<e10> Streptozocin </e10> has been reported to prolong the elimination half-life of <e20> doxorubicin </e20> and may lead to severe bone marrow suppression;
mechanism	<e10> Sulfamethoxazole </e10> may inhibit the hepatic metabolism of <e20> phenytoin </e20> .
mechanism	At a #-g dose, <e10> sulfamethoxazole </e10> produced a slight but significant increase in the half-life of <e20> phenytoin </e20> but did not produce a corresponding decrease in the metabolic clearance rate.
mechanism	<e12> Sulfonamides </e12> can also displace <e20> methotrexate </e20> from plasma protein-binding sites, thus increasing free methotrexate concentrations.
mechanism	Reduced absorption of <e10> folic_acid </e10> and digoxin have been reported when those agents were administered concomitantly with <e20> sulfasalazine </e20> .
mechanism	Reduced absorption of folic_acid and <e10> digoxin </e10> have been reported when those agents were administered concomitantly with <e20> sulfasalazine </e20> .
mechanism	<e12> MAO-A_inhibitors </e12> reduce <e20> sumatriptan </e20> clearance, significantly increasing systemic exposure.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, <e20> ketoconazole </e20> , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , <e20> itraconazole </e20> , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , <e20> clarithromycin </e20> , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , <e20> atazanavir </e20> , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , <e20> indinavir </e20> , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , <e20> nefazodone </e20> , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , <e20> nelfinavir </e20> , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , <e20> ritonavir </e20> , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , <e20> saquinavir </e20> , telithromycin , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , <e20> telithromycin </e20> , voriconizole ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with strong inhibitors of the CYP3A4 family (e,g,, ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , <e20> voriconizole </e20> ) may increases sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with inducers of the CYP3A4 family (e,g,, <e20> dexamethasone </e20> , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St, Johns Wort) may decrease sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with inducers of the CYP3A4 family (e,g,, dexamethasone , <e20> phenytoin </e20> , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St, Johns Wort) may decrease sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with inducers of the CYP3A4 family (e,g,, dexamethasone , phenytoin , <e20> carbamazepine </e20> , rifampin , rifabutin , rifapentin , phenobarbital , St, Johns Wort) may decrease sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with inducers of the CYP3A4 family (e,g,, dexamethasone , phenytoin , carbamazepine , <e20> rifampin </e20> , rifabutin , rifapentin , phenobarbital , St, Johns Wort) may decrease sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with inducers of the CYP3A4 family (e,g,, dexamethasone , phenytoin , carbamazepine , rifampin , <e20> rifabutin </e20> , rifapentin , phenobarbital , St, Johns Wort) may decrease sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with inducers of the CYP3A4 family (e,g,, dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , <e20> rifapentin </e20> , phenobarbital , St, Johns Wort) may decrease sunitinib concentrations.
mechanism	Co-administration of <e11> SUTENT </e11> with inducers of the CYP3A4 family (e,g,, dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , <e20> phenobarbital </e20> , St, Johns Wort) may decrease sunitinib concentrations.
mechanism	Administration of <e10> valproic_acid </e10> decreases oral clearance of <e20> temozolomide </e20> by about 5%.
mechanism	In a study in which # different drugs were tested, therapeutically relevant concentrations of <e10> tolbutamide </e10> , sodium_salicylate and sulfamethizole displaced protein-bound <e20> teniposide </e20> in fresh human serum to a small but significant extent.
mechanism	In a study in which # different drugs were tested, therapeutically relevant concentrations of tolbutamide , <e10> sodium_salicylate </e10> and sulfamethizole displaced protein-bound <e20> teniposide </e20> in fresh human serum to a small but significant extent.
mechanism	In a study in which # different drugs were tested, therapeutically relevant concentrations of tolbutamide , sodium_salicylate and <e10> sulfamethizole </e10> displaced protein-bound <e20> teniposide </e20> in fresh human serum to a small but significant extent.
mechanism	An increase in intracellular levels of <e10> methotrexate </e10> was observed in vitro in the presence of <e20> teniposide </e20> .
mechanism	<e10> Terbinafine </e10> decreases the clearance of <e20> caffeine </e20> by 19%.
mechanism	<e10> Terbinafine </e10> increases the clearance of <e20> cyclosporine </e20> by 15%.
mechanism	<e10> Terbinafine </e10> clearance is increased 100% by <e20> rifampin </e20> , a CyP450 enzyme inducer, and decreased 33% by cimetidine , a CyP450 enzyme inhibitor.
mechanism	<e10> Terbinafine </e10> clearance is increased 100% by rifampin , a CyP450 enzyme inducer, and decreased 33% by <e20> cimetidine </e20> , a CyP450 enzyme inhibitor.
mechanism	Pharmacokinetic data indicate that <e10> ketoconazole </e10> markedly inhibits the metabolism of <e20> terfenadine </e20> , resulting in elevated plasma terfenadine levels.
mechanism	Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of <e10> terfenadine </e10> and <e20> itraconazole </e20> in clinical trials of itraconazole and from foreign post-marketing sources.
mechanism	Macrolides : Clinical drug interaction studies indicate that <e10> erythromycin </e10> and clarithromycin can exert an effect on <e20> terfenadine </e20> metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent.
mechanism	Macrolides : Clinical drug interaction studies indicate that erythromycin and <e10> clarithromycin </e10> can exert an effect on <e20> terfenadine </e20> metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent.
mechanism	<e10> Thiabendazole </e10> may compete with other drugs, such as <e20> theophylline </e20> , for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels.
mechanism	As there is in vitro evidence that <e12> aminosalicylate_derivatives </e12> (e,g,, olsalazine , mesalazine , or sulphasalazine ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent <e20> thioguanine </e20> therapy.
mechanism	As there is in vitro evidence that aminosalicylate_derivatives (e,g,, <e10> olsalazine </e10> , mesalazine , or sulphasalazine ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent <e20> thioguanine </e20> therapy.
mechanism	As there is in vitro evidence that aminosalicylate_derivatives (e,g,, olsalazine , <e10> mesalazine </e10> , or sulphasalazine ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent <e20> thioguanine </e20> therapy.
mechanism	As there is in vitro evidence that aminosalicylate_derivatives (e,g,, olsalazine , mesalazine , or <e10> sulphasalazine </e10> ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent <e20> thioguanine </e20> therapy.
mechanism	The bioavailability of <e11> SKELID </e11> is decreased 80% by <e20> calcium </e20> , when calcium and SKELID are administered at the same time, and 60% by some aluminum - or magnesium -containing antacids , when administered # hour before SKELID .
mechanism	The bioavailability of SKELID is decreased 80% by calcium , when calcium and SKELID are administered at the same time, and 60% by some <e10> aluminum </e10> - or magnesium -containing antacids , when administered # hour before <e21> SKELID </e21> .
mechanism	The bioavailability of SKELID is decreased 80% by calcium , when calcium and SKELID are administered at the same time, and 60% by some aluminum - or <e10> magnesium </e10> -containing antacids , when administered # hour before <e21> SKELID </e21> .
mechanism	<e11> Aspirin </e11> may decrease bioavailability of <e21> SKELID </e21> by up to 50% when taken # hours after SKELID .
mechanism	The bioavailability of <e11> SKELID </e11> is increased 2-4 fold by <e20> indomethacin </e20> but is not significantly altered by coadministration of diclofenac .
mechanism	<e11> TOLECTIN </e11> and other nonsteroidal_anti-inflammatory_drugs have been reported to reduce the tubular secretion of <e20> methotrexate </e20> in an animal model, possibly enhancing the toxicity of methotrexate .
mechanism	TOLECTIN and other <e12> nonsteroidal_anti-inflammatory_drugs </e12> have been reported to reduce the tubular secretion of <e20> methotrexate </e20> in an animal model, possibly enhancing the toxicity of methotrexate .
mechanism	CYP3A4 Inhibitors: <e10> Ketoconazole </e10> , an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of <e20> tolterodine </e20> when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions).
mechanism	Administration of <e10> paclitaxel </e10> in combination with <e21> HERCEPTIN </e21> resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a #-fold increase in HERCEPTIN serum levels in clinical studies.
mechanism	<e10> Trimethoprim </e10> may inhibit the hepatic metabolism of <e20> phenytoin </e20> .
mechanism	<e10> Trimethoprim </e10> , given at a common clinical dosage, increased the <e20> phenytoin </e20> half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%.
mechanism	<e10> Trimethoprim </e10> , given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the <e20> phenytoin </e20> metabolic clearance rate by 30%.
mechanism	In vitro perfusion of isolated rat liver has shown that <e10> cimetidine </e10> caused a significant reduction in <e20> trimetrexate </e20> metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.
mechanism	Based on an in vitro rat liver model, nitrogen substituted <e12> imidazole_drugs </e12> ( clotrimazole , ketoconazole , miconazole ) were potent, non-competitive inhibitors of <e20> trimetrexate </e20> metabolism.
mechanism	Based on an in vitro rat liver model, nitrogen substituted imidazole_drugs ( <e10> clotrimazole </e10> , ketoconazole , miconazole ) were potent, non-competitive inhibitors of <e20> trimetrexate </e20> metabolism.
mechanism	Based on an in vitro rat liver model, nitrogen substituted imidazole_drugs ( clotrimazole , <e10> ketoconazole </e10> , miconazole ) were potent, non-competitive inhibitors of <e20> trimetrexate </e20> metabolism.
mechanism	Based on an in vitro rat liver model, nitrogen substituted imidazole_drugs ( clotrimazole , ketoconazole , <e10> miconazole </e10> ) were potent, non-competitive inhibitors of <e20> trimetrexate </e20> metabolism.
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e11> Sanctura </e11> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, <e20> digoxin </e20> , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ).
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e11> Sanctura </e11> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , <e20> procainamide </e20> , pancuronium , morphine , vancomycin , metformin and tenofovir ).
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e11> Sanctura </e11> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , procainamide , <e20> pancuronium </e20> , morphine , vancomycin , metformin and tenofovir ).
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e11> Sanctura </e11> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , procainamide , pancuronium , <e20> morphine </e20> , vancomycin , metformin and tenofovir ).
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e11> Sanctura </e11> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , procainamide , pancuronium , morphine , <e20> vancomycin </e20> , metformin and tenofovir ).
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e11> Sanctura </e11> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , procainamide , pancuronium , morphine , vancomycin , <e20> metformin </e20> and tenofovir ).
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e11> Sanctura </e11> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e,g, digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and <e20> tenofovir </e20> ).
mechanism	A study published in # found that <e10> vigabatrin </e10> causes a statistically significant increase in plasma clearance of <e20> carbamazepine </e20> .
mechanism	In 1984, Drs Rimmer and Richens at the University of Wales reported that administering <e10> vigabatrin </e10> with <e20> phenytoin </e20> lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy.
mechanism	Drug Interactions: Women on oral <e12> contraceptives </e12> have shown a significant increase in plasma <e22> vitamin_A </e22> levels.
mechanism	Limited evidence suggests that <e10> ascorbic_acid </e10> may influence the intensity and duration of action of <e20> bishydroxycoumarin </e20> .
